Ananth Ravi joined Traferox as Chief Operating Officer in September 2025, where he spearheads the company’s product pipeline and oversees all critical operational verticals. He brings 20 years of experience as a medical device executive and a clinical medical physicist.
Prior to joining Traferox, Ananth served as President and CEO of MOLLI Surgical, where he led the company through a high-growth trajectory that culminated in its successful acquisition by Stryker. Under his leadership, MOLLI Surgical revolutionized breast cancer localization with a wire-free, radiation-free technology that achieved rapid clinical adoption across the globe. His subsequent role as Managing Director at Stryker further solidified his expertise in navigating large-scale integrations and building global commercialization strategies for Stryker Breast Care.
Ananth holds a Ph.D. in Medical Biophysics from the University of Toronto, providing a strong technical foundation for his executive leadership. He is a recipient of Ontario’s prestigious Human Touch Award and previously led the renowned brachytherapy program at Sunnybrook. He specializes in bridging the gap between complex R&D and commercial scalability, ensuring that innovative technologies are effectively positioned for market leadership and operational excellence.